Abstract 107P
Background
Tumor stroma consists of a complex network of safeguards for tumor proliferation. Tumour stromal imaging using fibroblast-activated protein-tagged radionuclide provides a metabolic-radiological quantum of tumor stromal content. Tumors rich in stroma have been traditionally associated with poorer disease-free outcomes. Our study correlates between standard uptake values (SUV) in fibroblast imaging to tumor stromal ratio evaluated pathologically and the response to radiation therapy in locally advanced carcinoma rectum.
Methods
50 patients of carcinoma Rectum with all patients having undergone cancer associated Fibroblast PET CT scan prior to starting neoadjuvant chemoradiation. Tumors having SUV max > 10 were considered as High. Metabolic activity in tumor site was compared to Tumor stromal ratio and response to radiation was evaluated in histopathological report. Patients were classified into High TSR (<50% Stromal content) and Low Tumor Stroma Ratio (>50% Stromal content).
Results
7 patients who had complete pathological response all had high TSR and SUV mean 20.4. 34 patients had <50% residual disease 67% had high TSR and SUV mean 17.6 and 34% had low TSR and SUV mean of 21.44. 9 patients had >50% residual disease had 77% low TSR and high SUV mean 25.11(Range- 9.51-92.33). Patients with both Low TSR [ >50% stromal content] and SUV Max > 10 have poor pathological response compared to patients with low TSR. In the low stromal content irrespective of SUV the local control was good. Table: 107P
| High TSR | Low TSR | High SUV | Low SUV | |
| Complete response | 7(32%) | 0 | 4(15.4%) | 3(12.5%) |
| <50% Residual disease | 23(71.8%) | 11(61%) | 14(53.8%) | 20(83.3%) |
| >50% Residual disease | 2(6.2%) | 7(39%) | 8(30.8%) | 1(4.2%) |
Conclusions
High Tumor Stromal Ratio showed better complete and partial response to neoadjuvant chemoradiation in locally advanced carcinoma rectum. Tumors with high stromal content were observed to have higher SUV values in fibroblast stromal imaging and the same were also more commonly associated with suboptimal response. The need for dose escalation for the same has to be explored for better tumor control.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract